Welcome to Circassia
Circassia is a newly-established, clinical-stage specialty biopharmaceutical company focused on developing medicines designed to control immune system responses.
The Company's initial focus is on the development and commercialisation of a range of allergy therapeutics, based on its proprietary technology, which have the potential to transform current treatment. With its portfolio of allergy products progressing through development, the company is broadening its pipeline into other areas where immune system control is essential. The first of these is transplant rejection.
The Company is well funded having completed a first round fund raising in January 2007 and a second round fund raising in January 2008, and is supported by a syndicate of widely respected institutional and venture capital investors. The Company is managed by a particularly strong team, chaired by Sir Richard Sykes, and run by experienced executives Charles Swingland and Steve Harris. Overall, the management team brings a wealth of experience from major pharmaceutical companies, as well as the biotechnology and specialty pharmaceutical industries.
Did you know?
Over 20% of the population are allergic to grass pollen